| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -0.9% | +0.2% | -2.7% |
| 20D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +1.6% | -1.4% | -8.0% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -1.9% | -4.6% | -14.7% |
| 120D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -12.5% | -12.5% | -19.7% |
COMPANY RESEARCH
Genus plc
GNS.L · United Kingdom · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：45.3 / 100
1 insiders · 1 purchase events · €59k net purchases
Europe #871 · United Kingdom #232
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+10.5 / 35
How many distinct insiders bought in the cluster
Purchase size+17.8 / 25
Purchase value relative to company size and liquidity
Role+13.0 / 20
The seniority and relevance of participating insiders
Recency+0.0 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Insider role contributes less on the current role scale
- ⚠ Purchase activity is becoming less recent
The role contribution uses the inverted role input of the current European model.
Buying concentration
100%
Largest buyer：Celia Baxter · 50k GBP
Gross qualified purchase transaction-line value：50k GBP
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Celia Baxter | 21.39512 GBP | Jun 29, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-06-29 to 2026-06-29
- Current breadth input
- 0.300 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Celia Baxter · 50k GBP · Price 21.39512 GBP · Jun 29, 2026 - 🔴 33 other transaction line(s) are not counted as discretionary-buying evidence; 33 have zero price
Insider vs stock price
1 purchase day(s), 1 purchase line(s) in the 180-day window.
Daily close (GBp)Day with an insider purchase
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-06-29 | 1 | 1,039 +3.9% | 1,004 +0.4% | +35 +3.5 pts |
1 of 1 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (453 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
One insider bought, once (29 Jun). The share closed at 2,126.00 that day and at 2,208.00 most recently (+3.9%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −14.0% over these six months
The closing price of each day, from 2,568.00 on 2026-04-21 to 2,208.00 on 2026-10-07. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, +2.4%
Taken from the 491 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −14.0%, the typical one +2.4%, 16.4 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Nov
Dec
Jan
1Feb
Mar
Apr
May
1Jun
Jul
Aug
Sep
Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Celia Baxter | Board member | 1 | — | 50.0k GBP | 2026-06-29 | +3.9% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.300 | 10.5 |
| Qualified-buy size | 25% | 0.712 | 17.8 |
| Role informativeness (inverted) | 20% | 0.350 | 7.0 |
| Recency | 10% | 0.000 | 0.0 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13, neither column has changed. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
- The insider purchases themselvesBearone buyer only, latest purchase is old4 checked, under the threshold · 3 missing
- Share price and trading2 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results2 missing
- Company actionsBullcompany is buying back shares
Bull case · the buying is informative
- Company actionsThe company announced 4 transactions in its own shares in the last 30 days (latest 2026-10-12); the 4 read are all purchases. The company is buying its own shares while its insiders buy.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.Record: after 4,732 earlier disclosures like this, the median 60-session excess return was −2.7%, within 1 percentage point of all comparable disclosures (−3.3%).
- The latest purchase was 110 days ago (2026-06-29). A reporting period has passed since, so what the buyers knew then may already be public.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- The company's market value is not captured, so the purchases cannot be stated as a share of the business or of its trading volume.
- No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. The one purchase line does not mention a plan, but a bare “Purchase of 2,336 ordinary shares” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 7, 1 close to it
- BearThe share price changed −16% over six months (three months +11%, one month −3.6%). Counted for the bear side from a fall of 20%. close to the threshold
- Either1 insider bought in the last 180 days and 1 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- Bear0 of 1 buyer filed as a person closely associated with a manager. Counted for the bear side from half.
- EitherNet purchases of €59k in 180 days. Bull from €1.0M, bear when all purchases total under €25k.
- BearNo insider sale is recorded in the same 180 days.
- BearOver three months the share price changed +11% and the median of 271 Healthcare companies changed −6.3%: ahead by 17 points. Counted for the bear side from 20 points behind.
- BearPublished net short positions total 0.72% of the share capital. Counted for the bear side from 2%. On 2026-10-02 it was 0.31%: up 0.41 points since.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
45.3 / 100
Latest recorded score
→ +0.0 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)
- Recorded snapshots
- 35
- First snapshot
- 2026-08-26
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Recency-0.1 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 46.9
- 45.4
- 45.3
- 45.3
- 45.3
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-26 | 46.9 |
| 2026-08-27 | 46.9 |
| 2026-08-28 | 45.4 |
| 2026-08-31 | 45.4 |
| 2026-09-01 | 45.4 |
| 2026-09-02 | 45.4 |
| 2026-09-03 | 45.4 |
| 2026-09-04 | 45.4 |
| 2026-09-07 | 45.4 |
| 2026-09-08 | 45.4 |
| 2026-09-09 | 45.3 |
| 2026-09-10 | 45.3 |
| 2026-09-11 | 45.3 |
| 2026-09-14 | 45.3 |
| 2026-09-23 | 45.3 |
| 2026-09-24 | 45.3 |
| 2026-09-25 | 45.3 |
| 2026-09-28 | 45.3 |
| 2026-09-29 | 45.3 |
| 2026-09-30 | 45.3 |
| 2026-10-01 | 45.3 |
| 2026-10-02 | 45.3 |
| 2026-10-03 | 45.3 |
| 2026-10-04 | 45.3 |
| 2026-10-05 | 45.3 |
| 2026-10-06 | 45.3 |
| 2026-10-07 | 45.3 |
| 2026-10-08 | 45.3 |
| 2026-10-09 | 45.3 |
| 2026-10-12 | 45.3 |
| 2026-10-13 | 45.3 |
| 2026-10-14 | 45.3 |
| 2026-10-15 | 45.3 |
| 2026-10-16 | 45.3 |
| 2026-10-18 | 45.3 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +3.9% | +3.9% | +3.9% |
| 20D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +8.3% | +8.3% | +8.3% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +3.1% | +3.1% | +3.1% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +1.1% | +1.1% | +1.1% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 36.2%
- Beta
- —
- Avg daily volume
- £3.5M
VALUATION
- Market cap
- —
- P/E
- —
FUNDAMENTALS
- Profit margin
- 2.9%
- ROE
- 4.1%
- Industry
- —
Prices to 07 Oct 2026: price cache (Eulerpool). From the company's annual report ↗, fiscal year ended 30 Jun 2025: Profit margin, ROE. It does not affect the insider score or rank.
Disclosed net short positions
- Aggregate net short
- 0.72%
- Latest position date
- 09 Oct 2026
The FCA publishes one aggregate figure per issuer, the sum of all positions notified to it, and does not name the holders. Source: FCA · read 18 Oct 2026
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Market history is too old for this snapshot; ratios are withheld.
Market-data coverage: 251 verified sessions · Latest session: 2026-10-07 · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
- Insider filing announcement · published 2026-09-17 · trade date 2026-09-17
- Insider filing announcement · published 2026-09-16 · trade date 2026-09-16
- Insider filing announcement · published 2026-06-29 · trade date 2026-06-29
Unfold all 9 filings
- Insider filing announcement · published 2026-09-17 · trade date 2026-09-17
- Insider filing announcement · published 2026-09-16 · trade date 2026-09-16
- Insider filing announcement · published 2026-06-29 · trade date 2026-06-29
- Insider filing announcement · published 2026-05-13 · trade date 2026-05-13
- Insider filing announcement · published 2026-04-13 · trade date 2026-04-13
- Insider filing announcement · published 2026-04-01 · trade date 2026-04-01
- Insider filing announcement · published 2026-03-04 · trade date 2026-03-04
- Insider filing announcement · published 2026-02-27 · trade date 2026-02-27
- Insider filing announcement · published 2025-11-27 · trade date 2025-11-27
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
2 qualifying purchase disclosure(s) · 2 transaction line(s)
Jun 29, 2026Purchase of 2,336 ordinary shares.
Celia Baxter · Non-Executive Director
Ordinary shares of 10p each GB0002074580 · 2336 shares × 21.39512 GBP · —
Open filingFeb 27, 2026Purchase of 1,728 ordinary shares.
Celia Baxter · Non-Executive Director
Ordinary shares of 10p each GB0002074580 · 1728 shares × 28.92865 GBP · —
Open filingShowing 2 of 2 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 49 other transaction(s)
Sep 17, 2026Conditional award granted as PSUs under the LTIP over ordinary shares in Genus.
Jorgen Kokke · Chief Executive Officer
Ordinary shares of 10p each. GB0002074580 · 42172 shares × 0 GBP · —
Open filingSep 17, 2026Conditional award granted as PSUs under the LTIP over ordinary shares in Genus.
Andy Russell · Chief Financial Officer
Ordinary shares of 10p each. GB0002074580 · 27613 shares × 0 GBP · —
Open filingSep 17, 2026Conditional award granted as PSUs under the LTIP over ordinary shares in Genus.
Mark Birri · Chief Corporate Development Officer
Ordinary shares of 10p each. GB0002074580 · 10471 shares × 0 GBP · —
Open filingUnfold all 46 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-17 | 2026-09-17 | Matt Culbertson | Chief Operating Officer Genus PIC | Conditional award granted as PSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 17554 | Open filing |
| 2026-09-17 | 2026-09-17 | Jim Low | Chief Operating Officer Genus ABS | Conditional award granted as PSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 15705 | Open filing |
| 2026-09-17 | 2026-09-17 | Elena Rice | Chief Scientific Officer | Conditional award granted as PSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 15381 | Open filing |
| 2026-09-17 | 2026-09-17 | Angelle Rosata | Chief Human Resources Officer | Conditional award granted as PSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 13936 | Open filing |
| 2026-09-17 | 2026-09-17 | Lucie Grant | Group General Counsel & Company Secretary | Conditional award granted as PSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 14930 | Open filing |
| 2026-09-17 | 2026-09-17 | Jorgen Kokke | Chief Executive Officer | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 21086 | Open filing |
| 2026-09-17 | 2026-09-17 | Andy Russell | Chief Financial Officer | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 13806 | Open filing |
| 2026-09-17 | 2026-09-17 | Mark Birri | Chief Corporate Development Officer | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 5235 | Open filing |
| 2026-09-17 | 2026-09-17 | Matt Culbertson | Chief Operating Officer Genus PIC | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 8777 | Open filing |
| 2026-09-17 | 2026-09-17 | Jim Low | Chief Operating Officer Genus ABS | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 7852 | Open filing |
| 2026-09-17 | 2026-09-17 | Elena Rice | Chief Scientific Officer | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 7690 | Open filing |
| 2026-09-17 | 2026-09-17 | Angelle Rosata | Chief Human Resources Officer | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 6968 | Open filing |
| 2026-09-17 | 2026-09-17 | Lucie Grant | Group General Counsel & Company Secretary | Conditional award granted as RSUs under the LTIP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 7465 | Open filing |
| 2026-09-17 | 2026-09-17 | Jorgen Kokke | Chief Executive Officer | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 11788 | Open filing |
| 2026-09-17 | 2026-09-17 | Andy Russell | Chief Financial Officer | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 11090 | Open filing |
| 2026-09-17 | 2026-09-17 | Mark Birri | Chief Corporate Development Officer | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 2446 | Open filing |
| 2026-09-17 | 2026-09-17 | Matt Culbertson | Chief Operating Officer Genus PIC | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 4142 | Open filing |
| 2026-09-17 | 2026-09-17 | Jim Low | Chief Operating Officer Genus ABS | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 2906 | Open filing |
| 2026-09-17 | 2026-09-17 | Elena Rice | Chief Scientific Officer | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 3536 | Open filing |
| 2026-09-17 | 2026-09-17 | Lucie Grant | Group General Counsel & Company Secretary | Conditional award granted under the DBP over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 3314 | Open filing |
| 2026-09-16 | 2026-09-16 | Jorgen Kokke | Chief Executive Officer | Exercise of nil-cost options under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 111388 | Open filing |
| 2026-09-16 | 2026-09-16 | Matt Culbertson | Chief Operating Officer, Genus PIC | Exercise of nil-cost options under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 23183 | Open filing |
| 2026-09-16 | 2026-09-16 | Elena Rice | Chief Scientific Officer | Exercise of nil-cost options under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 20308 | Open filing |
| 2026-09-16 | 2026-09-16 | Angelle Rosata | Chief Human Resources Officer | Exercise of nil-cost options under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 18399 | Open filing |
| 2026-09-16 | 2026-09-16 | Matt Culbertson | Chief Operating Officer, Genus PIC | Exercise of nil-cost options under the DSBP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 1772 | Open filing |
| 2026-09-16 | 2026-09-16 | Elena Rice | Chief Scientific Officer | Exercise of nil-cost options under the DSBP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 1459 | Open filing |
| 2026-09-16 | 2026-09-16 | Angelle Rosata | Chief Human Resources Officer | Exercise of nil-cost options under the DSBP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 1237 | Open filing |
| 2026-09-16 | 2026-09-16 | Mark Birri | Chief Corporate Development Officer | Release of conditional share awards under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 2246 | Open filing |
| 2026-09-16 | 2026-09-16 | Mark Birri | Chief Corporate Development Officer | Release of conditional share awards under the PSP. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 1726 | Open filing |
| 2026-05-13 | 2026-05-13 | Jorgen Kokke | Chief Executive | Exercise of nil-cost options granted on 2 May 2023 over ordinary shares in Genus in respect of buyout of compensation forfeited from his previous employer . | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 7649 | Open filing |
| 2026-04-13 | 2026-04-13 | Jim Low | Chief Operating Officer, Genus ABS | Purchase of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | 25.54701 GBP | GBP | 15 | Open filing |
| 2026-04-13 | 2026-04-13 | Jim Low | Chief Operating Officer, Genus ABS | Award of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 5 | Open filing |
| 2026-04-01 | 2026-04-01 | Jim Low | Chief Operating Officer, ABS | Vesting of share awards and release of shares on 31 March 2026 under a Restricted Stock Award over ordinary shares in Genus. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 7307 | Open filing |
| 2026-04-01 | 2026-04-01 | Jim Low | Chief Operating Officer, ABS | Sale of shares arising from the vesting of share awards under Restricted Stock Award to offset income tax and social security liabilities due on the vesting. | Ordinary shares of 10p each GB0002074580 | 24.05 GBP | GBP | 2756 | Open filing |
| 2026-03-04 | 2026-03-04 | Jim Low | Chief Operating Officer, Genus ABS | Purchase of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | 25.5 GBP | GBP | 17 | Open filing |
| 2026-03-04 | 2026-03-04 | Jim Low | Chief Operating Officer, Genus ABS | Award of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 5 | Open filing |
| 2026-03-04 | 2026-03-04 | Jim Low | Chief Operating Officer, Genus ABS | Purchase of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | — | GBP | 22 | Open filing |
| 2026-03-04 | 2026-03-04 | Jim Low | Chief Operating Officer, Genus ABS | Award of Genus plc Ordinary Shares of 10p each under the Company's International Share Incentive Plan. | Ordinary shares of 10p each GB0002074580 | 0 GBP | GBP | 8 | Open filing |
| 2025-11-27 | 2025-11-27 | Jorgen Kokke | Chief Executive Officer | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 18327 | Open filing |
| 2025-11-27 | 2025-11-27 | Andy Russell | Chief Financial Officer | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 11701 | Open filing |
| 2025-11-27 | 2025-11-27 | Mark Birri | Chief Corporate Development Officer | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 4436 | Open filing |
| 2025-11-27 | 2025-11-27 | Matt Culbertson | Chief Operating Officer Genus PIC | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 7629 | Open filing |
| 2025-11-27 | 2025-11-27 | Jim Low | Chief Operating Officer Genus ABS | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 6825 | Open filing |
| 2025-11-27 | 2025-11-27 | Elena Rice | Chief Scientific Officer | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 6684 | Open filing |
| 2025-11-27 | 2025-11-27 | Angelle Rosata | Chief Human Resources Officer | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 6056 | Open filing |
| 2025-11-27 | 2025-11-27 | Lucie Grant | Group General Counsel & Company Secretary | Award of Restricted Share Units granted under the Genus 2025 Long Term Incentive Plan over ordinary shares in Genus. | Ordinary shares of 10p each. GB0002074580 | 0 GBP | GBP | 5914 | Open filing |
Showing 49 of 49 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- GNS.L
- ISIN
- GB0002074580
- Sector
- Healthcare
- Industry
- Biotechnology
Company logos by Parqet